Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

FDA Tells Public to Stop Using Certain Innova COVID-19 Antigen Tests

Last updated on

The U.S. Food and Drug Administration (FDA) is warning the public to stop using the Innova SARS-CoV-2 Antigen Rapid Qualitative Test for diagnostic use. The concerns are:

  • The performance of the test is not established and presents a health-risk.
  • Labeling distributed with certain configurations of the test includes performance claims. These claims did not accurately reflect the performance estimates observed during the clinical studies of the tests.
  • The test has not been authorized, cleared, or approved by the FDA for commercial distribution or use in the United States, as required by law.

The Innova SARS-CoV-2 Antigen Rapid Qualitative Test is also distributed under the names:

  • Innova COVID-19 Self-Test Kit (three tests)
  • Innova SARS-CoV-2-Antigen Rapid Qualitative Test (seven tests)
  • Innova SARS-CoV-2-Antigen Rapid Qualitative Test (25 tests).

Read the full FDA notice.